Request Trial
1 February 2013Big Pharma

Hub and spoke? Life sciences in Northern France

The French biotech and life sciences industry is, if not necessarily booming, more than pulling its weight in a tough economic climate. In the teeth of the worst crisis in living memory, France finds itself playing host to some of Europe’s most innovative companies in the sector, driven by clusters of research and development across the country.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
Part II: The race to replace semaglutide heats up
23 March 2026   With Novo Nordisk's core semaglutide patent expired in India last week, the company that built one of the most successful drugs in pharmaceutical history is already fighting on a new front. So what comes next?
Big Pharma
Sandoz strikes fresh biosimilar deal with South Korean biotech
19 March 2026   The Swiss generics giant secures global commercialisation rights as partnership targets multi-billion-dollar loss-of-exclusivity opportunity.
Big Pharma
INTA: ‘New normal’ for in-house counsel as budgets fall
16 March 2026   Research from the International Trademark Association finds in-house counsel taking on more strategic work while facing shrinking budgets, prompting a shift towards alternative billing and greater use of AI.


Editor's picks

Closing the women's health gap offers ‘benefits for all’
Biotechnology
Closing the women's health gap offers ‘benefits for all’
7 April 2026

Editor's picks

Biotechnology
Closing the women's health gap offers ‘benefits for all’
7 April 2026
Americas
Argentina’s patent reset: Why pharma can no longer ignore Latin America's second-largest market
1 April 2026
Europe
WIPR debuts Global In-House Elite 2026
26 March 2026
Biotechnology
mRNA litigation: Who’s winning, who’s filing, and what’s next
25 March 2026
Americas
Masimo convinces judge that Apple took secrets—but it’s not enough
19 March 2026
Americas
Abbott IP chief: ‘Firms without AI policies scare me’
5 March 2026

More features

Gilead to pay up to $5bn for antibody-drug conjugates push
Closing the women's health gap offers ‘benefits for all’
Bausch reaches deal with competitor over IBS drug generic
European patent offices raise fees
UPC refuses early knockout in Illumina–Element dispute
Argentina’s patent reset: Why pharma can no longer ignore Latin America's second-largest market
IndiaMart v CDSCO: A test of intermediary liability
CRISPR priority feud ends at USPTO as board reaches decision